In China, access to the Drug Master File (DMF) is typically restricted to regulatory authorities, such as the National Medical Products Administration (NMPA), and the DMF holder. Pharmaceutical companies may access relevant sections with the holder’s permission for product registration or manufacturing purposes, ensuring confidentiality and compliance with regulations.
